Diplomat Will Dispense ZEJULA(TM) to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- April 19th, 2017
- 169 views
The nation’s largest independent specialty pharmacy has been selected to the specialty pharmacy panel to dispense ZEJULA™ (niraparib).
FLINT, Mich. / CRWE PRESS RELEASE / April 19, 2017 – Diplomat Pharmacy, Inc. (NYSE: DPLO), has been selected to the specialty pharmacy panel to distribute ZEJULA™ (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The Food and Drug Administration (FDA) recently approved ZEJULA as a once-daily oral maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy. ZEJULA is the first poly ADP-ribose polymerase inhibitor to be approved by the FDA that does not require BRCA mutation or other biomarker testing.
To learn more about Diplomat’s oncology program, visit diplomat.is/areas-of-excellence/oncology.
“For women living with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, ZEJULA™ (niraparib) offers new hope as a promising treatment option,” said Paul Urick, Diplomat’s president.
Epithelial ovarian, fallopian tube, and primary peritoneal cancer are cancers of the tissue covering the ovary or lining the fallopian tube or abdominal wall (peritoneum). According to the American Cancer Society, more than 22,000 women will be diagnosed with these cancers in 2017. Combined, cancer of the ovaries, fallopian tubes, and peritoneum are the fifth most common cause of cancer-related death in women in the United States.
ZEJULA is manufactured by TESARO, Inc. TESARO anticipates launching ZEJULA in the United States in late April. For full prescribing information, click here.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
Kali Lucas, Public Relations Specialist
810.768.9580 | firstname.lastname@example.org
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | email@example.com
Source: Diplomat Pharmacy, Inc.